F Baeke1, T L Van Belle1, T Takiishi1, L Ding1, H Korf1, J Laureys1, C Gysemans1, C Mathieu2. 1. Laboratory for Clinical and Experimental Endocrinology (CEE), Campus Gasthuisberg O&N1, Herestraat 49 bus 902, 3000, Leuven, Belgium. 2. Laboratory for Clinical and Experimental Endocrinology (CEE), Campus Gasthuisberg O&N1, Herestraat 49 bus 902, 3000, Leuven, Belgium. Chantal.Mathieu@med.kuleuven.be.
Abstract
AIMS/HYPOTHESIS: Anti-CD3 monoclonal antibodies remain the most promising immune therapy for reversing recent-onset type 1 diabetes. However, current clinical trials have revealed their major drawback, namely the narrow therapeutic window in which low doses are ineffective and higher doses that preserve functional beta cell mass cause side effects. Strategies that sidestep these limitations while preserving or improving anti-CD3's therapeutic efficiency are essential. We hypothesised that combining a potent vitamin D(3) analogue (TX527), ciclosporin A (CsA) and anti-CD3 would act to lower the dose while maintaining or even boosting therapeutic efficacy to counteract autoimmune destruction of transplanted islets. METHODS: This study involved the use of syngeneic islet transplantation, immunofluorescence microscopy, immune phenotyping by flow cytometry, RT-PCR analysis, and in vitro and in vivo suppression assays. RESULTS: Combination therapy with TX527, CsA and anti-CD3 was well tolerated on the basis of weight, bone and calcium variables. Remarkably, combining all three agents at sub-therapeutic doses greatly reduced recurrent autoimmune responses to a grafted islet mass (mean ± SEM: 79.5 ± 18.6 days; p < 0.01), by far exceeding the therapeutic efficacy of monotherapy (24.8 ± 7.3 days for anti-CD3) and dual therapy (25.5 ± 12.4 days for anti-CD3+CsA). Combination therapy surpassed anti-CD3 monotherapy in reducing islet infiltration by effector/memory phenotype CD8(+) T cells, as well as by reducing proinflammatory cytokine responses and increasing the frequency of T regulatory cells that were functional in vitro and in vivo, and acted in a cytotoxic T lymphocyte antigen 4-dependent manner. CONCLUSIONS/ INTERPRETATION: Combining the immunomodulatory actions of anti-CD3 mAb with CsA and the vitamin D(3) analogue, TX527, delivers therapeutic efficacy in an islet-transplanted NOD mouse model of diabetes.
AIMS/HYPOTHESIS: Anti-CD3 monoclonal antibodies remain the most promising immune therapy for reversing recent-onset type 1 diabetes. However, current clinical trials have revealed their major drawback, namely the narrow therapeutic window in which low doses are ineffective and higher doses that preserve functional beta cell mass cause side effects. Strategies that sidestep these limitations while preserving or improving anti-CD3's therapeutic efficiency are essential. We hypothesised that combining a potent vitamin D(3) analogue (TX527), ciclosporin A (CsA) and anti-CD3 would act to lower the dose while maintaining or even boosting therapeutic efficacy to counteract autoimmune destruction of transplanted islets. METHODS: This study involved the use of syngeneic islet transplantation, immunofluorescence microscopy, immune phenotyping by flow cytometry, RT-PCR analysis, and in vitro and in vivo suppression assays. RESULTS: Combination therapy with TX527, CsA and anti-CD3 was well tolerated on the basis of weight, bone and calcium variables. Remarkably, combining all three agents at sub-therapeutic doses greatly reduced recurrent autoimmune responses to a grafted islet mass (mean ± SEM: 79.5 ± 18.6 days; p < 0.01), by far exceeding the therapeutic efficacy of monotherapy (24.8 ± 7.3 days for anti-CD3) and dual therapy (25.5 ± 12.4 days for anti-CD3+CsA). Combination therapy surpassed anti-CD3 monotherapy in reducing islet infiltration by effector/memory phenotype CD8(+) T cells, as well as by reducing proinflammatory cytokine responses and increasing the frequency of T regulatory cells that were functional in vitro and in vivo, and acted in a cytotoxic T lymphocyte antigen 4-dependent manner. CONCLUSIONS/ INTERPRETATION: Combining the immunomodulatory actions of anti-CD3 mAb with CsA and the vitamin D(3) analogue, TX527, delivers therapeutic efficacy in an islet-transplanted NOD mouse model of diabetes.
Authors: Lisl K M Shoda; Daniel L Young; Saroja Ramanujan; Chan C Whiting; Mark A Atkinson; Jeffrey A Bluestone; George S Eisenbarth; Diane Mathis; Aldo A Rossini; Scott E Campbell; Richard Kahn; Huub T C Kreuwel Journal: Immunity Date: 2005-08 Impact factor: 31.745
Authors: Adam P Kohm; Julie S Williams; Allison L Bickford; Jeffrey S McMahon; Lucienne Chatenoud; Jean-François Bach; Jeffrey A Bluestone; Stephen D Miller Journal: J Immunol Date: 2005-04-15 Impact factor: 5.422
Authors: Astrid G S van Halteren; Odette M Tysma; Evelyne van Etten; Chantal Mathieu; Bart O Roep Journal: J Autoimmun Date: 2004-11 Impact factor: 7.094
Authors: Robert Zeiser; Vu H Nguyen; Andreas Beilhack; Martin Buess; Stephan Schulz; Jeanette Baker; Christopher H Contag; Robert S Negrin Journal: Blood Date: 2006-03-07 Impact factor: 22.113
Authors: Lei Ding; Conny A Gysemans; Geert Stangé; Yves Heremans; Yixing Yuchi; Tatiana Takiishi; Hannelie Korf; Marie Chintinne; Richard D Carr; Harry Heimberg; Daniel Pipeleers; Chantal Mathieu Journal: PLoS One Date: 2014-09-30 Impact factor: 3.240
Authors: Hannelie Korf; Laura Breser; Jelter Van Hoeck; Janet Godoy; Dana P Cook; Benoit Stijlemans; Elien De Smidt; Carolien Moyson; João Paulo Monteiro Carvalho Mori Cunha; Virginia Rivero; Conny Gysemans; Chantal Mathieu Journal: PLoS One Date: 2017-11-02 Impact factor: 3.240
Authors: Koenraad Philippaert; Andy Pironet; Margot Mesuere; William Sones; Laura Vermeiren; Sara Kerselaers; Sílvia Pinto; Andrei Segal; Nancy Antoine; Conny Gysemans; Jos Laureys; Katleen Lemaire; Patrick Gilon; Eva Cuypers; Jan Tytgat; Chantal Mathieu; Frans Schuit; Patrik Rorsman; Karel Talavera; Thomas Voets; Rudi Vennekens Journal: Nat Commun Date: 2017-03-31 Impact factor: 14.919